Deubiquitinating Enzymes in Parkinson’s Disease

Citations Over TimeTop 15% of 2020 papers

Abstract

Mitochondrial dysfunction and neurodegeneration have been directly correlated in many neurodegenerative disorders. Parkinson's disease (PD) in particular has been extensively studied in this context because of its well-characterized association with mitophagy, a selective type of autophagy that degrades mitochondria. Mitophagy is triggered by ubiquitin modification of proteins residing on the surface of mitochondria. Therefore, mitophagy is subject to suppression by deubiquitination. In recent years, many deubiquitinase enzymes (DUBs) emerged as therapeutic targets to compensate hindered mitophagy in PD. It is reasonable that inhibition of specific DUBs should induce mitophagy by blocking deubiquitination of mitochondrial proteins, although the signaling pathway is not always that linear. The broad aspect suggests that there could be cross talks among DUBs, which may in turn have synergistic effect to rescue the disease progression. In this short review we have highlighted DUBs that hold therapeutic value in the field of neurodegenerative diseases, PD in particular.

Related Papers

• → Selective autophagy as a potential therapeutic target for neurodegenerative disorders(2018)349 cited
• → PPPDE1 is a novel deubiquitinase belonging to a cysteine isopeptidase family(2017)25 cited
• → Deubiquitinating Enzymes in Parkinson’s Disease(2020)24 cited
• → Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy pathways(2024)10 cited
• → Deubiquitinating Enzymes: Their Functions and Substrate Specificity(2004)59 cited